We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Proteome Sciences Plc | LSE:PRM | London | Ordinary Share | GB0003104196 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.40 | -10.26% | 3.50 | 3.00 | 4.00 | - | 139,794 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 7.78M | 1.33M | 0.0045 | 8.67 | 11.51M |
Date | Subject | Author | Discuss |
---|---|---|---|
17/5/2024 19:30 | But you let CJP and squad do it for 20 years and lap it up.They did it again yesterday,how long before enough is enough.?? | peverill | |
17/5/2024 19:16 | Where's the fun in that?? | peverill | |
17/5/2024 17:22 | #92948, Is he talking about me? Bar Room Monkeys: 1 Brains as Big as Brazil: 0 | jeffian | |
17/5/2024 16:50 | #92950 You don’t have to. It is your choice. | monte1 | |
17/5/2024 16:27 | Not really theirs alone - we have to put up with their whining day after day. | small crow | |
17/5/2024 16:23 | I think that is their business, isn’t it? | barry evans | |
17/5/2024 16:18 | If someone's not happy, and they don't see any prospects, why don't they sell??? | small crow | |
17/5/2024 13:55 | Let's be honest,they didn't have a clue when anything was due for release or even if it would be released.A complete rabble,everything they ever licensed has been shelved.Galaxy the same and a Director of said company sat there,not a clue.Richard!!!!!wha | peverill | |
17/5/2024 12:03 | I think the outcome would have been the same for me. I've never won anything on the horses! | jeffian | |
17/5/2024 11:44 | I think the suggestion by Pike of 'going to the Grand National' is quite possibly the must useful utterance by any PRM director ever, and one which I wish I'd heard in 2001 instead of 2024 ... the outcome of that alternative would surely have been better ... | bluemango | |
17/5/2024 11:40 | blue, I've edited my post above after checking the webcast again. | jeffian | |
17/5/2024 11:34 | To be fair to Randox, you simply can't rush these things. Imo 7 or 8 years is nothing. There's surely got to be much more pen-pushing, meetings and further meetings and risk assessments and further meetings before anything appears from Randox and possibly not in our lifetimes. (Edited to correct the number of years of procrastination - thanks jeffian) | bluemango | |
17/5/2024 10:46 | No he didn't (I watched it online; it's 25 min in). In response to a leading question submitted by a shareholder (you?!) "Will Randox release their stroke test this year?", Pike referred to it as "the perennial question which has appeared for the last 7/8 years". The response was 'we hope so', but we are not in the driving seat and Randox will not release anything until it is 'market ready' (whatever that means). He said he had no specific knowledge and Randox did not have to release any information, though he suggested you might find out more 'if you went to the Grand National'. (Randox are sponsors). He "hoped" it would appear in the second half of the year. I bet he does. There was also a question about the latest markers for tau and the reported encouraging progress in this area. Pike said plainly that "none of the tau tests in the market infringe PRM's IP" though it was possible that some of their markers may become involved in combination with others at a later stage. So much for the "Toll Booth" eh?! (Edited for correction following a review of the meeting) | jeffian | |
17/5/2024 09:30 | wasjobber. What does he mean by 'this'? | dominiccummings | |
17/5/2024 08:15 | At the AGM yesterday Ian Pike confirmed that Randox look to be releasing their stroke blood test this year! Thanks Ian. STRONG BUY | wasjobber | |
16/5/2024 22:50 | re 92932 proteomespeak It is still not a good long-term platform and significant growth looks required from here to reassure on even the gross cash position. I suggest it is in that context that current performance insight is required rather than about “customer contact” and “quotations provided”. Ahead of further balance sheet insight, an £11.2 million market cap continued avoid/sell. shareprophets | elpirata | |
16/5/2024 19:13 | Just watched the AGM,and it kind of explains everything and why the company is in the position it finds itself in.What an absolute bunch of amateurs.I don't think they know what's going on themselves,so where all the guff on here comes from I don't know.All them to pay plus the lab staff.Not a chance we will ever see a return here. | peverill | |
16/5/2024 18:24 | Well, Christopher has aged a bit since I met him all those years ago.A better year ahead looks likely. Pity none of the gang want to buy some shares to back their confidence... | 049balt | |
16/5/2024 11:46 | There's a presentation on the Investormeet website at 12.00 if you're interested GRC. | jeffian | |
16/5/2024 10:59 | So how was the agm? Any news on Stroke? Were they same as always or is there a spark of life in the old place. Anyone see behind the face masks? | glennrcharles | |
16/5/2024 10:08 | The service business will not keep this afloat alone,it needs licensing agreements for the IP.Namely AD,but everyone is skirting around the patents as they please or they don't need them.Then they decide to out license to some obscure company that low and behold a PRM director is in hoc with,laughable. | peverill | |
16/5/2024 10:06 | They're still very wedded to Proteome-speak, aren't they? "Since the start of 2024, we have seen significant customer engagement and interest in proteomics services reflected by the considerable increase in customer contact and quotations provided" "Sales" is a word which doesn't seem to exist in their dictionary. | jeffian | |
16/5/2024 10:01 | Last years AGM statement The Board is confident that the progress over the recent years has created an excellent platform for further development of the Group. Following the investment made over the last two years, a strong order book, new projects, high customer interest, our healthy cash position and recently announced expansion into the US, the Group has a strong base for 2023 and beyond. Proteome Sciences is well set to achieve a step-change in growth which gives the Board increased confidence that the business can continue to significantly grow revenue and EBITDA in the coming years." | amt | |
16/5/2024 09:59 | Haha,never understood the need for multiple personalities,I know it exists,the Mrs has a few ,but on a free BB,naaah!! | peverill |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions